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Like eukaryotic and archaeal viruses, which coopt the host’s
cellular pathways for their replication, bacteriophages have
evolved strategies to alter the metabolism of their bacterial host.
SPO1 bacteriophage infection of Bacillus subtilis results in
comprehensive remodeling of cellular processes, leading to con-
version of the bacterial cell into a factory for phage progeny
production. A cluster of 26 genes in the SPO1 genome, called the
host takeover module, encodes for potentially cytotoxic pro-
teins that specifically shut down various processes in the bacte-
rial host, including transcription, DNA synthesis, and cell divi-
sion. However, the properties and bacterial targets of many
genes of the SPO1 host takeover module remain elusive.
Through a systematic analysis of gene products encoded by the
SPO1 host takeover module, here we identified eight gene prod-
ucts that attenuated B. subtilis growth. Of the eight phage gene
products that attenuated bacterial growth, a 25-kDa protein
called Gp53 was shown to interact with the AAA chaperone
protein ClpC of the ClpCP protease of B. subtilis. Our results
further reveal that Gp53 is a phage-encoded adaptor-like pro-
tein that modulates the activity of the ClpCP protease to enable
efficient SPO1 phage progeny development. In summary, our
findings indicate that the bacterial ClpCP protease is the target
of xenogeneic (dys)regulation by a SPO1 phage– derived factor
and add Gp53 to the list of antibacterial products that target
bacterial protein degradation and therefore may have utility for
the development of novel antibacterial agents.
Much like eukaryotic and archaeal viruses, which derail the
host’s cellular processes to facilitate viral replication, phages
have evolved complex strategies to acquire their bacterial hosts.
To successfully infect and replicate in the bacterial cell, many
phages encode proteins that specifically interfere with essential
biological processes of the host bacterium, including transcrip-
tion, translation, DNA replication, and cell division (1). Phage
proteins that interfere with host processes are typically small in
size (on average 160 amino acid residues) and are usually
produced at high levels early in the infection cycle (2). SPO1 is a
prototypical lytic phage of Bacillus subtilis, and its genes are
categorized as early, middle, and late to reflect the time of their
expression during SPO1 infection in B. subtilis. The majority of
SPO1 early genes associated with host takeover are in the
12.4-kb terminal region of the genome, which includes the
26-gene host takeover module (Fig. 1A) (3, 4). The genes within
the host takeover module, genes 37– 60, have several hallmarks
to suit the characteristics of phage proteins that interfere with
host processes: they are mostly small and produced early in
infection and contain promoters and ribosome binding sites
characteristic of highly expressed genes (3, 5). Many of them
have been shown previously to be involved in the shutoff of
bacterial DNA and RNA synthesis (gp38, gp39, gp40, gp44,
gp50, and gp51) or to inhibit cell division (gp56) during SPO1
infection (6 –8). Further, plasmid-borne expression of gp44,
gp56, and gps50/51 in B. subtilis has been shown to attenuate
growth and reduce viability, respectively (6, 8, 9). With the
exception of the product of gp44, which has been postulated to
interact with B. subtilis RNA polymerase (9, 10), the bacterial
targets and mechanism of action of the gene products encoded
by the host takeover module of SPO1 remain elusive. Clearly,
phages and their gene products represent an underexploited
resource for potentially developing novel antibacterial strate-
gies and to gain new insights into bacterial cell function and
regulation. In this study, we undertook a systematic approach
to identify genes in the SPO1 phage host takeover module that
had a detrimental effect on B. subtilis growth and unveil the
biological role of the product of gp53, which interacts with the
Hsp100/Clp family member ClpC of B. subtilis.
Results
The effect of SPO1 host takeover module genes on B. subtilis
growth
We wanted to identify genes in the SPO1 host takeover mod-
ule that had a detrimental effect on B. subtilis growth by grow-
ing bacteria in the absence and presence of isopropyl 1-thio--
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Figure 1. SPO1 host takeover module genes that attenuate B. subtilis growth. A, schematic of the SPO1 host takeover module. The molecular masses
(kilodaltons) of the individual gene products are shown above each gene in bold, and operons are indicated by dotted lines. The predicted positions of
promoters are shown as arrows, indicating the direction of transcription. B, schematic of the experimental procedure used to identify SPO1 host takeover
module gene products that attenuate the growth of B. subtilis. O/N, overnight. C, graph showing the A600 values of B. subtilis cultures at 5 h of growth in the
presence of IPTG, which induces expression of the individual host takeover module genes. Gene products shown in red displayed 50% or more attenuation
compared with control cells expressing GFP. D, graphs showing growth curves (red) of B. subtilis cultures expressing SPO1 host takeover module genes that
attenuated growth 50% or more and that of control cultures (see key). E, graphs showing growth curves (red) of B. subtilis cultures expressing the individual
operons of the SPO1 host takeover module and that of control cultures (see key). The lag time preceding growth and growth rate () of B. subtilis cultures
expressing SPO1 host takeover module gene product(s) is shown in the bottom panels in D and E. Error bars in C–E represent S.E. (n  3). Statistical analyses were
performed by one-way ANOVA (**, p  0.01; ***, p  0.001).
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D-galactopyranoside (IPTG),3 which allowed plasmid-borne
(pHT01 (11)) expression of the 26 host takeover genes either
individually or with other genes in their respective operons (Fig.
1B). Any effect of the gene products of the host takeover mod-
ule on B. subtilis growth was monitored by determining the cell
density by measuring light absorbance of the culture at 600 nm
after a 5-h period of incubation at 37 °C (Fig. 1B). As the con-
trol, we used bacteria containing the pHT01 plasmid expressing
GFP. As shown in Fig. 1C, when the SPO1 phage host takeover
module genes were expressed individually in B. subtilis, the
growth of bacteria expressing Gp37, Gp41, Gp42, Gp44, Gp46,
Gp53, Gp56, and Gp60 was attenuated by 50% or more com-
pared with control cells expressing GFP. The individual graphs
in Fig. 1D show growth curves of B. subtilis expressing Gp37,
Gp41, Gp42, Gp44, Gp46, Gp53, Gp56, and Gp60 over a period
of 8 h. We noted that, under our conditions, plasmid-borne
expression of Gp37, Gp41, Gp42, Gp44, Gp46, Gp53, Gp56, and
Gp60 slowed the growth rate () to varying degrees but, in the
cases of Gp37, Gp44, Gp53, Gp56, and Gp60, also attenuated
growth by extending the lag time preceding growth (Fig. 1D).
Further, it seemed that leaky expression (which occurs in the
absence of the inducer) of Gp53, Gp56, and Gp60 also attenu-
ated growth to some degree, indicating that the latter SPO1
gene products are potentially more toxic to B. subtilis than the
others (i.e. Gp37, Gp41, Gp42, Gp44, and Gp46). The expres-
sion of the SPO1 host takeover module genes together with
other genes in their respective operons revealed that operons
containing genes shown to attenuate growth when expressed
individually, as expected, attenuated growth efficiently (Fig. 1E)
with the following exceptions. First, Gp38, Gp39, and Gp40,
when expressed together in operon 1 and operon 2, appeared to
act synergistically and displayed an enhanced ability to attenu-
ate bacterial growth (compare Fig. 1, C and E). Further, we note
that, in B. subtilis, cells in which the host takeover module
genes in operon 1 and 2 as well as 7 are expressed together do
not recover growth under our experimental conditions, as
observed when the genes are expressed individually (compare
Fig. 1, D and E). This indicates that the host takeover module
gene products within each operon functionally interact and
thus have a more pronounced effect on host physiology than
when expressed individually. Second, we note that Gp46 is no
longer able to attenuate growth of B. subtilis when expressed
together with Gp45 in operon 3. This implies that Gp45 some-
how mitigates the antagonistic effect of Gp46 on B. subtilis
cells. Overall, we conclude that recombinant forms of Gp37,
Gp41, Gp42, Gp44, Gp46, Gp53, Gp56, and Gp60 have a detri-
mental effect on B. subtilis growth in the absence of SPO1
infection, presumably by targeting essential cellular processes.
Gp53 interacts with the ClpC ATPase of the ClpCP protease in
B. subtilis
Because Gp53 was experimentally more tractable than the
other SPO1 host takeover factor gene products, we next
focused on identifying the target(s) of Gp53 in B. subtilis. We
constructed an N-terminal His6-tagged version of Gp53 to
identify its bacterial target(s) by conducting a pulldown assay
using whole-cell extracts of exponentially growing B. subtilis
cells. Initially, we investigated whether the histidine-tagged
version of Gp53 retained its ability to attenuate B. subtilis
growth under the conditions described in Fig. 1C. As shown in
Fig. 2A, the activity of N-terminal His6-tagged Gp53 and its
untagged counterpart did not differ significantly. For simplic-
ity, from here on, the N-terminal His6-tagged version of Gp53
will be referred to as Gp53. To perform the pulldown assays,
purified Gp53 was immobilized onto nickel resin, and the
“charged” resin was incubated with whole-cell extracts pre-
pared from exponentially growing B. subtilis cells (Fig. 2B). The
resin was then washed extensively to remove any nonspecific
interactions before analysis by SDS-PAGE. As shown in Fig. 2C,
when the pulldown assay was conducted in the presence of
Gp53, we detected specific enrichment of a band on the SDS-
3 The abbreviations used are: IPTG, isopropyl 1-thio--D-galactopyranoside;
BTH, bacterial two-hybrid; AmBic, ammonium bicarbonate; ANOVA, anal-
ysis of variance; DWB, double walker B.
Figure 2. Gp53 interacts with the ClpC ATPase of the ClpCP protease in
B. subtilis. A, bar chart comparing the efficacy of growth attenuation of a
culture of B. subtilis either expressing N-terminal His6-tagged Gp53 (red) or
untagged Gp53 (gray). B, schematic of the pulldown assay used to identify the
bacterial target(s) of Gp53. C, a representative image of an SDS-PAGE gel
showing results of the pulldown assay with Gp53 and whole-cell extracts
(WCL) of B. subtilis. The band specifically enriched in reactions containing
immobilized Gp53 is indicated by an arrowhead in lane 3. D, a representative
image of an SDS-PAGE gel showing results of the pulldown assay with puri-
fied Gp53 and N-terminal FLAG-tagged ClpC. The migration positions of Gp53
and ClpC are indicated. E, bar chart showing the results from the bacterial
two-hybrid interaction assay with ClpC and mutant variants of Gp53. The
ClpC-binding activity of the Gp53 mutants as a percentage of WT Gp53 activ-
ity is indicated. Error bars in A and E represent S.E. (n  3). Statistical analyses
were performed by one-way ANOVA (ns, not significant; ***, p  0.001).
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PAGE gel (Fig. 2C, arrowhead, lane 3), which was not observed
in the control reactions with “uncharged” resin (i.e. in the
absence of any immobilized protein) (Fig. 2C, lane 2). The
enriched band was investigated by linear quadrupole ion trap
Fourier transform MS analysis, which revealed it to be the
Hsp100/Clp family member ClpC, the ATPase subunit of the
ClpCP protease in B. subtilis. To further validate that Gp53
interacts with ClpC, we repeated the pulldown assay using puri-
fied C-terminal FLAG-tagged ClpC and nickel resin with
immobilized Gp53. As shown in Fig. 2D, FLAG-tagged ClpC
appears to weakly interact with the nickel resin (lane 4) in the
absence of Gp53. However, a specific enrichment of ClpC is
clearly seen in the presence of Gp53 (Fig. 2D, lane 3).
To establish that the interaction between Gp53 and ClpC is
specific and to identify amino acids in Gp53 important for bind-
ing to ClpC, we conducted a BLAST search using standard
search parameters and SPO1 Gp53 as a query sequence. Three
homologous proteins and one protein fragment from SPO1-
related phages were found (Fig. S1), with amino acids (Leu-83,
Val-87, Arg-94, Leu-95, and Lys-101) conserved across all five
sequences. All of these residues were individually substituted
with alanine, apart from the positively charged residues Arg-94
and Lys-101, which were also replaced with negatively charged
glutamic acid residues. Next, a bacterial two-hybrid (BTH)
interaction assay was performed to determine how the amino
acid substitutions in Gp53 affected its ability to interact with
ClpC. We opted for the bacterial adenylate cyclase two-hybrid
system, in which both gp53 and clpC were coexpressed in a
cya Escherichia coli strain DHM1 as fusions to one of two
fragments (T18 and T25) of the catalytic domain of Bordetella
pertussis adenylate cyclase (12). Interaction of two-hybrid pro-
teins results in a functional complementation between T18 and
T25, leading to cAMP synthesis, and, consequently, transcrip-
tional activation of the lactose operon that can be detected in a
-gal assay. As shown in Fig. 2E, reactions with Gp53 variants
harboring an alanine substitution (V87A or L95A) and charge-
reversal substitution at Arg-94 (R94E) displayed significantly
lower -gal activity compared with the reaction with WT Gp53.
We conclude that the proximally located amino acid residues
Val-87, Arg-94, and Leu-95 in Gp53 are important determi-
nants for binding to ClpC.
Gp53 stimulates the ATPase activity of ClpC in a manner
analogous to B. subtilis adaptor proteins
A major role of ClpC in B. subtilis is ATP hydrolysis-depen-
dent unfolding and loading of substrate proteins for degrada-
tion by the protease ClpP. Substrate specificity upon ClpC is
conferred by different adaptor proteins that interact with ClpC
and trigger oligomerization, thereby allowing subsequent for-
mation of a complex with ClpP monomers that come together
to form the proteolytic chamber (Fig. 3A). In other words, the
adaptor protein is an obligatory activator of the ClpCP protease
(13). Because binding of the adaptor protein, such as the well-
documented MecA protein, has been shown to stimulate the
basal ATPase activity of ClpC, we initially tested how Gp53
binding affected the ATPase activity of ClpC. The results
shown in Fig. 3B indicate dose-dependent stimulation of the
ATPase activity of ClpC by Gp53. Control experiments with the
mutant variant of Gp53 harboring the R94E substitution, which
displayed compromised ability to bind ClpC in the BTH assay
(Fig. 2E), revealed that the stimulation of ClpC’s basal ATPase
activity was due to the specific action of Gp53 (Fig. 3B). We next
wanted to determine whether Gp53 competed with native
adaptor proteins for binding to ClpC. Using MecA as a model
adaptor protein (14 –16), we initially conducted ATPase assays
to determine whether Gp53 and MecA can bind simultaneously
to ClpC and can act synergistically to stimulate the basal
ATPase activity of ClpC. As shown in Fig. 3C, addition of MecA
(reaction I) or Gp53 (reaction II) resulted in stimulation of the
basal ATPase activity of ClpC. However, the presence of MecA
and Gp53 together in the reaction, regardless of the order of
addition, did not result in an increase in ClpC’s ATPase activity
to a level higher than the ATPase activity seen when MecA and
Gp53 were added individually (Fig. 3C, compare reactions I and
II with III and IV). Therefore, we conclude that MecA and Gp53
do not synergistically stimulate the ATPase activity of ClpC.
However, because MecA and Gp53 individually stimulate the
basal ATPase activity of ClpC to comparable levels (Fig. 3C,
reactions I and II), it is not possible to tell whether they are
competing for ClpC binding in the context of this assay. There-
fore, to directly determine that Gp53 competes with MecA for
binding to ClpC, we used a modified version of the BTH assay
described in Fig. 2E. In this assay, MecA and ClpC were fused to
the T18 and T25 fragments, respectively, of the catalytic
domain of B. pertussis adenylate cyclase and transformed into
cya E. coli strain DHM1 containing a plasmid in which Gp53
expression was under the control of the L-arabinose–inducible
araB promoter. We expected that if Gp53 competed with
MecA for binding to ClpC, then the productive interaction
between MecA and ClpC would be disrupted when expression
of Gp53 is induced with L-arabinose (Fig. 3D, schematic). As
expected, the results revealed that the -gal activity originating
from the productive interaction between MecA and ClpC was
reduced by 3-fold in the presence of L-arabinose (Fig. 3D).
Additional control BTH assays revealed that Gp53 and MecA
do not interact (Fig. S2), suggesting that the reduction in -gal
activity originating from the productive interaction between
MecA and ClpC in the presence of Gp53 (Fig. 3D) was not due
to MecA being titrated away from ClpC by Gp53. Further, pre-
vious studies (17–20) revealed the N-terminal domain (amino
acid residues 1–141) and a linker region (amino acid residues
412– 471) in ClpC to be important for binding to the adaptor
proteins MecA and McsB. Therefore, to determine whether the
Gp53- and MecA/McsB-interacting regions on ClpC overlap or
are different, we fused six fragments of ClpC (Fig. 3E, sche-
matic) to T25 and used either MecA or Gp53 fused to T18 in the
BTH assay. The results shown in Fig. 3E clearly reveal that both
MecA and Gp53 bind to overlapping surfaces on ClpC, with the
N-terminal domain of ClpC accounting for much of the binding
and the linker region restoring the interaction to that seen with
full-length ClpC. In summary, we conclude that Gp53, al-
though it clearly stimulates the ATPase activity of ClpC in a
manner analogous to B. subtilis adaptor proteins, is likely to
compete with the latter for binding to ClpC. Thus, by inference,
we suggest that Gp53 could affect the normal functioning of the
Xenogeneic modulation of the ClpCP protease














Figure 3. Gp53 stimulates the ATPase activity of ClpC and competes with the B. subtilis adaptor protein MecA for binding to ClpC. A, schematic showing how
the ATP hydrolysis and adaptor protein mediated formation of the functional ClpCP protease in B. subtilis (adapted from Molière et al. (32)). B, graph showing the
amount of ATP hydrolyzed (Pi release, micromolar) as a function of time by ClpC (0.2 M) alone and in the presence of different amounts of Gp53 (0.2, 0.4, and 1 M).
Numerical ATPase rates are shown on the right. C, bar chart showing results from the ATPase assay (as in B) in which ClpC (50 nM) was incubated with equimolar
amounts of MecA (reaction I), Gp53 (reaction II), or MecA and Gp53 (added to the reaction in different orders, reactions III and IV). The amount of Pi released (micromolar)
is expressed as -fold change with respect to the reaction with ClpC alone, i.e. its basal ATPase activity. D, bottom panel, bar chart showing the results from the modified
bacterial two-hybrid interaction assay to demonstrate that Gp53 competes with MecA for binding ClpC. Top panel, the assay setup (see text for details). E, bottom panel,
bar chart showing the results from the bacterial two-hybrid assay demonstrating binding of Gp53 or MecA to different domains of ClpC (as shown in the top panel). In
B–E, error bars represent S.E. (n  3). Statistical analyses were performed by one-way ANOVA (ns, not significant; **, p  0.01; *** p  0.001).
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ClpCP protease by excluding the functionally obligatory adap-
tor proteins from interacting with it.
Gp53 modulates the activity of the ClpCP protease in
B. subtilis
Because adaptor proteins like MecA are required for activa-
tion and to confer substrate specificity upon the ClpCP prote-
ase, we next investigated the effect of Gp53 on the protease
activity of ClpCP. Therefore, to determine whether Gp53
inhibits the proteolytic activity of the ClpCP protease or merely
modulates its activity during SPO1 development in B. subtilis,
we conducted in vitro protein degradation assays. As shown in
Fig. 4A, left panel, in the absence of any substrate, MecA, as
expected (21), was degraded by ClpCP protease. Similarly,
Gp53 was also degraded, albeit at a slower rate than MecA, by
the ClpCP protease (Fig. 4A, right panel). Further, consistent
with the results in Fig. 3, the results in Fig. 4B confirmed that
both Gp53 and MecA compete for binding to ClpC because
addition of both proteins together resulted in an overall
decreased rate of degradation of either protein (compare lanes
3, 4, 6, and 7 in Fig. 4A with lanes 2 and 3 in Fig. 4B).
Next we conducted protein degradation assays using the
intrinsically unfolded -casein as a model substrate in the pres-
ence of MecA and/or Gp53. Consistent with previous studies,
the control reaction in the absence of MecA or Gp53 did not
result in the degradation of -casein (Fig. 4C). However, degra-
dation of -casein was detected in the presence of MecA (com-
pare lanes 1–3 in Fig. 4C with lanes 2– 4 in Fig. 4D). Interest-
ingly, although ClpC is activated by Gp53 (Fig. 3), leading to
degradation of Gp53 by ClpCP (Fig. 4A), -casein was not
degraded in the presence of Gp53 (Fig. 4E). Consistent with the
results in Fig. 4B, the presence of Gp53 and MecA together in
the reaction decreased the rate of -casein degradation (Fig.
4F): following 90 min of incubation, 10-fold -casein was left
intact compared with reactions without Gp53 (compare lane 4
in Fig. 4D with lane 3 in Fig. 4F). Interestingly, additional exper-
iments with a different adaptor protein, McsB/A (McsB
requires McsA for activation (22)), revealed that Gp53 is less
efficient at competing for ClpC in the presence of McsB/A. As
shown in Fig. 4G, the rate of degradation of -casein in reac-
tions with McsB/A in the absence or presence of Gp53 was
indistinguishable (compare lanes 4 – 6 with lanes 1–3). Overall,
the results clearly indicate that Gp53 does not inhibit the pro-
teolytic activity of ClpCP protease but could compete with
some host adaptor proteins to modulate the activity of ClpCP
protease during SPO1 development in B. subtilis.
To provide evidence of Gp53-mediated modulation of the
activity of ClpCP protease on a proteome-wide scale, we com-
pared the proteome profiles of B. subtilis cells expressing Gp53
(Fig. 4H, left panel) with those of cells not expressing Gp53 (Fig.
4H, right panel) by LC-MS. The log/log plot of the mass-to-
retention time of the peptides revealed that the majority of pep-
tides within the B. subtilis proteome remained unaffected in the
presence of Gp53 (Fig. 4H, left panel). However, it appeared
that a targeted subset of peptides is significantly altered by
2-fold or more specifically because of the presence of Gp53 (Fig.
4H, left panel). Of the 197 peptides that have altered abundance
in Gp53-expressing cells, 79 were sequenced using an auto-
MS/MS method and were mapped to 34 unique proteins
involved in diverse biological activities (Table S3). This equates
to 1% of the total known proteome of B. subtilis (proteome ID
UP000001570, https://www.uniprot.org/proteomes)4 (24) and
is likely an underestimate because not all peptides were
sequenced using this method. Importantly, we note that pep-
tides of proteins shown in Table S3 are not just found with
higher abundance (suggesting protection from degradation)
but also with lower abundance (suggesting possible accelerated
degradation) in the presence of Gp53. In conclusion, the results
unambiguously reveal that Gp53 could compete with some bac-
terial adaptor proteins for binding to the ClpC and therefore
does not inhibit but modulates the activity of the ClpCP prote-
ase during SPO1 development.
Compromised ClpCP protease activity affects the efficacy of
SPO1 development in B. subtilis
We posited that if the role of Gp53 is to modulate the activity
of ClpCP protease to allow successful development of SPO1 in
B. subtilis, then a clpC B. subtilis strain (IH25) would provide
a compromised host environment for SPO1 development com-
pared with WT B. subtilis cells. Thus, we compared the ability
of SPO1 to lyse an exponentially growing culture of WT and
clpC B. subtilis by measuring cell density (light absorbance at
A600) as a function of time following SPO1 infection. The
growth of WT and clpC strains under our experimental con-
ditions did not detectably differ (Fig. 5A). A rapid drop in cell
density, indicating cell lysis, was observed after 30 min in the
WT B. subtilis culture infected with SPO1 at A600 0.2 (Fig. 5B).
As expected, the clpC B. subtilis culture infected with SPO1
continued to grow for a further 20 min, reaching a higher cell
density than the WT strain before undergoing cell lysis (Fig.
5B). As shown in Fig. 5C, similar results were obtained with
B. subtilis strains containing ClpC, which is unable to hydrolyze
ATP because of two mutations within the Walker B domain in
both ATPase domains (clpC DWB, strain IH140 (18)) or unable
interact with ClpP because of a deletion in a region required for
binding to ClpP (clpC-loop VGF::GGR, strain IH217 (25)). In
the case of the clpC DWB and clpC-loop mutant B. subtilis
strains, the culture continued to grow for a further 10 min com-
pared with the WT culture before cell lysis occurred. Overall,
the results are consistent with the findings above and indicate
that modulating the activity of ClpCP protease by Gp53, but not
its inhibition, is required for optimal SPO1 development in
B. subtilis.
Discussion
A common theme by which phages affect host physiology to
benefit phage progeny development is through the modulation
or inhibition of bacterial cellular processes (1, 2). Previous stud-
ies (6 –9) revealed that SPO1 infection results in remodeling of
several host processes by seven (Gp38, Gp39, Gp40, Gp44,
Gp50, Gp51, and Gp56) of the 26 genes encoded by the host
takeover module. Specifically, although the molecular details
still remain elusive, Gp38, Gp39, Gp40, Gp44, Gp50, and Gp51
4 Please note that the JBC is not responsible for the long-term archiving and
maintenance of this site or any other third party– hosted site.
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have been implicated in shutoff of host macromolecular bio-
synthetic processes (RNA, DNA, and protein synthesis) and
Gp56 in inhibition of bacterial cell division (6 –8). This study
revealed that Gp37, Gp41, Gp42, Gp44, Gp46, Gp53, Gp56, and
Gp60 attenuate the growth of B. subtilis in the absence of SPO1
infection (Fig. 1). It seems that the individual effects of some
host takeover module gene products (e.g. Gp38, Gp39, and
Gp40) might not be sufficient to affect bacterial growth. In sup-
port of this view, coexpression of Gp38, Gp39, and Gp40, which
constitute operon 2 of the host takeover module (Fig. 1A),
resulted in increased growth attenuation, presumably through
synergistic activities of Gp38, Gp39, and Gp40. As phage
genomes tend to be compact and efficient, it is remarkable that
SPO1 has evolved many elaborate mechanisms to take over
B. subtilis cells. We predict that the action of each individual
host takeover module gene product is carefully regulated in a
temporally coordinated manner and that some functionally
interact with each other to bring about the desired effect (e.g.
Gp38, Gp39, and Gp40) or control their functionalities. The
observation that coexpression of Gp45 with Gp46 (operon 3)
counteracts the effect of the latter on B. subtilis growth (Fig. 1E)
further underscores this view. Further, it is tempting to specu-
late that genes within operon 3 of the host takeover module are
akin to a toxin/anti-toxin module. Previous investigations by
Stewart and co-workers (6 –9) have shown that mutations in
genes 38, 39, 40, 44, 50, 51, and 56 do not decrease the burst size
of SPO1 infection. It is important to remember that most stud-
ies of phage– host interactions, like the present one and those
listed above, are conducted under “optimal” laboratory condi-
tions. Thus, it is possible that some of the SPO1 host takeover
module gene products might only be required for infecting and
replicating in bacteria in different physiological states, e.g. a
nutrient-starved population of bacteria (26). For example, Gray
et al. (27) reported recently that B. subtilis can exist in an olig-
otrophic state without sporulating. It would thus be interesting
to investigate whether some SPO1 host takeover gene products
and their targets become essential for SPO1 development in
B. subtilis experiencing oligotrophic growth conditions. Fur-
ther, our earlier work on the T7 phage led to the identification
of a T7 gene product involved in inhibition of the bacterial RNA
polymerase only in the stationary phase of growth (28).
The involvement of bacterial protein degradation machinery
in phage development is not uncommon, and well established
examples include lysis–lysogeny decision in phage  (29), DNA
replication/transcription decision in phage  (30), and inhibi-
tion of Lon protease by T4 (31). Thus, it seems that Gp53 is one
of a growing number of phage-encoded factors that are
involved in modulating the activity of host protein degradation
machinery optimal phage progeny development.
Under standard laboratory conditions, the absence of ClpC
had a subtle yet consistent detrimental effect on the efficacy of
SPO1 infection in B. subtilis (Fig. 5). Thus, it is possible that the
requirement for ClpC by SPO1 becomes more prominent
under more native and/or specific conditions for B. subtilis (see
above). The results reveal that SPO1 Gp53 competes with some
host adaptor protein(s) for binding to ClpC and thereby mod-
ulates the activity of the ClpCP protease. Because different
adaptor proteins can compete for binding to ClpC to confer
substrate specificity upon the ClpCP protease (14, 17), it seems
that Gp53 can be considered an adaptor-like protein produced
by a phage. Consistent with this view, the results revealed that
the binding site of Gp53 on ClpC is likely to overlap with that of
native adaptor proteins such as MecA or McsB (Fig. 3E), and,
Figure 4. Gp53 modulates the specificity of the ClpCP protease in B. subtilis. A, representative images of SDS-PAGE gels of in vitro degradation of MecA and
Gp53 by ClpCP protease. The intensities of the bands corresponding to MecA or Gp53 are shown in the graph relative to the intensity of the ClpP band in the
corresponding lanes. The migration positions of ClpC (1 M), MecA (1 M), Gp53 (1 M), and ClpP (1 M) are indicated. Pyruvate kinase (PK, 20 ng/ml) and
phosphoenolpyruvate (4 mM) were used as an ATP generation system. B, as in A, but equimolar amounts of MecA and Gp53 were added together. C, as in A, but
the in vitro degradation assays were conducted in the presence of 3 M -casein and in the absence of MecA or Gp53. D, as in C, but the in vitro degradation
assays were conducted in the presence of MecA. E, as in C, but the in vitro degradation assays were conducted in the presence of Gp53. F, as in C, but the in vitro
degradation assays were conducted in the presence of MecA and Gp53. G, as in C, but the in vitro degradation assays were conducted with McsA/B (1 M each)
in the absence and presence of Gp53. In A–G, the same color coding is used in the schematics, gels, and graphs to aid data interpretation. H, left panel, a log/log
plot comparing the accurate mass and retention time of peptides in whole-cell extracts of B. subtilis containing pHT08-Gp53 expressing Gp53 upon induction
by IPTG and control whole-cell extracts of B. subtilis containing pHT08-Gp53 to which no IPTG was added. A paired t test (p  0.05) was carried out to identify
peptides that had a -fold change in abundance of 2 or more and that lie on or outside of the diagonal outer green lines. Right panel, as in the left graph, but whole
cell-extracts of B. subtilis with and without IPTG added were compared, which demonstrated that the change in peptide abundance was specific to the
presence of Gp53.
Figure 5. Compromised ClpCP protease activity affects the efficacy of
SPO1 development in B. subtilis. A, graph showing the growth curves of
WT, clpC (IH25), clpC DWB (IH140), and clpC-loop (IH217) B. subtilis cultures.
B, graph showing the optical density as a function of time of a culture of
exponentially growing WT and clpC B. subtilis cells following infection with
SPO1 at A600 0.2. C, as in B, but with WT, clpC DWB, and clpC-loop B. subtilis
cells. Error bars in A–C represent S.E. (n  3).
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like native adaptor proteins, Gp53 becomes degraded by the
ClpCP protease in the absence of any substrates (Fig. 4B). Thus,
it is conceivable that Gp53 functionally mimics the role of a
B. subtilis adaptor protein, which, consequently, could result in
subversion of the ClpCP protease to benefit phage develop-
ment. However, the amino acid sequences of B. subtilis adaptor
proteins and Gp53 share very little sequence similarity (Fig. S3).
In conclusion, we propose the following two mutually exclusive
scenarios: (1) Gp53 can act like an adaptor-like protein, target
SPO1-derived substrates for proteolysis, and, consequently,
interferes with the recognition and targeting of bacterial sub-
strates by native (bacterial) adaptor proteins for proteolysis by
the ClpCP protease, and/or (2) Gp53 repurposes the ClpCP
protease to modulate the proteome of B. subtilis to benefit
SPO1 development. The fact that the ClpCP protease and its
adaptor proteins are involved in both regulatory (e.g. transcrip-
tion factors) and general (misfolded or damaged proteins) pro-
teolysis (32), it would seem that that a competing “xenogeneic”
adaptor-like protein such as Gp53 would have detrimental
pleiotropic effects on the growth of B. subtilis cells (Fig. 1).
Future work in the laboratory will be directed at experimentally
investigating these scenarios. Finally, we note that virus-di-
rected degradation of host proteins is not uncommon in
eukaryotic systems. For example, in the case of human papillo-
maviruses, the virus-encoded E6 and E6-AP proteins interact
with the cell cycle control protein p53 and target it for degra-
dation, increasing the oncogenic potential of human papillo-
maviruses (33).
The ClpC and ClpP proteins of Gram-negative and Gram-
positive bacteria have recently been recognized as viable targets
for antibiotic discovery, and a number of naturally occurring
antibacterial products deregulate the respective activities of
ClpC or ClpP, resulting in bacterial cell death (34, 35). With the
emerging interest in the use of phages and phage-encoded pro-
teins as sources of alternatives to antibiotics, this study reveals
that the ClpCP protease of B. subtilis and homologs in other
bacteria can be subjected to xenogeneic dysregulation by
phage-derived factors and adds Gp53 to the growing list of nat-
urally occurring antibacterial products that target the bacterial
protein degradation machinery.
Materials and methods
Plasmids, strains, and proteins
All plasmids used in this study for protein expression and
BTH assays were generated using standard molecular biology
procedures and are detailed in Table S1. pSCBAD-Gp53 was
made by Gibson assembly (36). The pSC101 plasmid (37) was
modified by inserting the regulatory region of pBAD33 (araC
promoter region, multiple cloning sites, and the rrnB T2 termi-
nator) between restriction sites XhoI and NsiI. All proteins
used in this study were purified by either Ni affinity chroma-
tography (for His6-tagged proteins, i.e. Gp53, MecA, and
ClpP) or anti-FLAG M2 affinity resin (for FLAG-tagged pro-
teins i.e. ClpC) using standard molecular biology proce-
dures. The details of plasmids used for protein purification
are shown in Table S1. All the strains used in this study are
shown in Table S2.
Bacterial growth assays
Unless otherwise stated, B. subtilis cultures were grown in
2xYT (16 g/liter tryptone, 10 g/liter yeast extract, 5.0 g/liter
NaCl) medium (Sigma) with 2% (w/v) glucose and appropriate
antibiotics at 37 °C. For the experiments shown in Figs. 1 and
2A, seed cultures were grown at 37 °C with shaking at 700 rpm
for 16 –18 h in a THERMOstar (BMG Labtech) plate incubator
by directly inoculating a colony into 200 l of 2xYT medium
containing 5 g/ml chloramphenicol and 2% (w/v) glucose (to
prevent leaky expression from the pHT01 vector) into a 48-well
plate (Greiner). The growth curves were also performed in
48-well plates in a SPECTROstar Nano Absorbance multiwell
plate reader (BMG Labtech). The seed cultures were A600-cor-
rected to 0.025 in 200 l of fresh 2xYT medium containing 5
g/ml chloramphenicol, 2% (w/v) glucose, and either water or 1
mM IPTG to induce the expression of SPO1 host takeover
genes. Cultures were incubated at 37 °C with shaking at 700
rpm. At least three biological and technical replicates were
performed.
Pulldown assays
These were performed as described previously (28) using
proteins specified in the main text and figures, with the follow-
ing amendments. Binding buffer (25 mM NaH2PO4, 50 mM
NaCl, 5 mM imidazole, and 5% glycerol (pH 7)), wash buffer (25
mM NaH2PO4, 50 mM NaCl, 15 mM imidazole, and 5% glycerol
(pH 7)), and samples were eluted by adding 50 l of Laemmli
2 concentrated SDS sample buffer to beads and boiled for 5
min prior to analysis by SDS-PAGE.
Bacterial two-hybrid interaction assays
These were carried out using the bacterial adenylate cyclase-
based two-hybrid system (Euromedex) and conducted accord-
ing to the manufacturer’s guidelines. Briefly, recombinant plas-
mids encoding proteins of interest fused to the T25 or T18
domain of adenylate cyclase were transformed into competent
DHM1 cells (see Table S1 for details of plasmids used). Trans-
formants were grown overnight at 30 °C in a 96-well plate in LB
medium containing ampicillin (100 g/ml), kanamycin (50
g/ml), and IPTG (0.5 mM). Each culture was then diluted 1:5 in
Z buffer (45 mM Na2HPO4–NaH2PO4 (pH 7), 10 mM KCl, 2 mM
MgSO47H2O, and 40 mM -mercaptoethanol), and cells were
permeabilized using 0.01% (w/v) SDS and 10% (v/v) chloro-
form. Each culture was again diluted 1:4 in Z buffer and equil-
ibrated at 28 °C before adding 0.4% (v/v) O-nitrophenol--gal-
actoside. Reactions were carried out in a SPECTROstar Nano
Absorbance multiwell plate reader (BMG Labtech) at 28 °C for
20 min, with measurement of A420 nm every 1 min. The -gal
activity is given in Miller units, with 1 Miller unit corresponding
to 1 nM O-nitrophenol--galactoside hydrolyzed per minute at
28 °C (after accounting for A600 correction and dilution fac-
tors). At least three biological and technical replicates were per-
formed for each measurement.
ATPase assays
The ATPase assay is based on colorimetric measurement of
the concentration of Pi from the hydrolysis of ATP. Reactions
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were carried out at 37 °C for the specified times in buffer con-
taining 100 mM KCl, 25 mM Tris-HCl (pH 8.0), 5 mM MgCl2, 0.5
mM DTT, 0.1 mM EDTA, 0.5 g/l BSA, and 4 mM ATP. ClpC,
MecA, and/or Gp53 were added at concentrations indicated in
the figures and figure legends. The amount of Pi in the reaction
was then quantified using PiColorLockTM detection reagent
(Innova Biosciences) according to the manufacturer’s guide-
lines. The data were corrected for buffer-only values to account
for any spontaneous degradation of ATP. At least three biolog-
ical and technical replicates were performed for each reaction.
ClpCP-mediated protein degradation assays
These were conducted exactly as described previously (15).
The protein components were present in the amounts indi-
cated in the figure legends.
LC-MS
Six biological replicates of B. subtilis containing pHT08
encoding His-Gp53 were grown to A600 0.5. Three replicates
were induced with 1 mM IPTG, and water was added to the
remaining three as uninduced controls. Cultures were left to
grow for 2 h and corrected to A600, and 2 and 5 ml were pelleted
at 3220  g for 10 min. Proteins were precipitated from the
pellets by methanol/chloroform extraction as described previ-
ously (23). The dried protein pellets were resuspended in 100 l
of 0.1 M ammonium bicarbonate (AmBic)–10% methanol. 125
mM DTT in 0.1 M AmBic–10% methanol was added and incu-
bated at 80 °C for 15 min. 250 mM 2-iodoacetamide in 0.1 M
AmBic–10% methanol was added and incubated at room tem-
perature in the dark for 30 min. Trypsin at 0.11 g/l was
added, and samples were incubated for 16 h at 37 °C. All sam-
ples were injected in a randomized order and separated on a
1290 LC system (Agilent) operating in normal flow mode at 200
l/min. 1 l of the sample was separated on a Zorbax Extend-
C18 column (1.8 m particle size, 5 cm length, 2.1 mm identity
(Agilent)). A 19.5-min method with the following gradient was
used: 97% buffer A (0.1% (v/v) formic acid in water), 3% buffer B
(0.1% (v/v) formic acid in acetonitrile). Buffer B was increased
to 40% over 12.5 min, followed by an increase to 100% buffer B
over 2 min, where it was held for 2 min. Buffer B was then
ramped back down to 3% over 1 min and equilibrated for 2 min
prior to the next injection. The 1290 LC system was coupled to
a 6550 iFunnel Q-ToF mass spectrometer (Agilent) equipped
with an iFunnel electrospray source and running MassHunter
data acquisition software. For relative peptide abundance, data
were acquired in MS-only mode over the 300 –1700 m/z range
at the rate of 1 spectrum/s. Peptides were identified using an
auto-MS/MS method selecting up to 20 precursors per cycle
with a threshold of 5000 counts and a charge state of 2 or
greater. Profinder B08 (Agilent) was used for peak list genera-
tion. The resulting MS-only files were imported into Mass Pro-
filer Professional (Agilent) for relative peptide abundance com-
parison. Samples grouped according to type and features (as
defined by accurate mass and retention time) were clustered for
further analysis. Results were filtered so that a feature was pres-
ent in all samples within both groups. Log/log of the intensity of
features in each sample group was plotted, and a paired t test
(p  0.05) was carried out to identify features that had a -fold
change of 2 or higher. LC-MS/MS data were extracted into peak
lists using SpectrumMill (Agilent). Database searching against
SwissProt was achieved using the following search parameters:
enzyme specificity, trypsin; charge states, 2 or greater; fixed
modification, cysteine carbaminoacetylation; variable modifi-
cations, methionine-oxidized. A score of 5 was set for accept-
ance of peptide assignments and 10 for protein identifications.
Peptides with a false discovery rate of more than 5% were
discarded.
SPO1 infection assays
Seed cultures of bacteria were grown at 37 °C with shaking at
700 rpm for 16 –18 h in a THERMOstar (BMG Labtech) plate
incubator by directly inoculating a colony into 1 ml of 2xYT
medium into a 24-well plate (Greiner). The infection curves
were also performed in 24-well plates in a SPECTROstar Nano
Absorbance multiwell plate reader (BMG Labtech). The seed
cultures were A600-corrected to 0.05 in 1 ml of fresh 2xYT
medium and incubated at 37 °C with shaking at 700 rpm. At
A600 0.2, a certain amount of SPO1 lysate was added in a 1:1
ratio of bacterial cells; phage particles and A600 measurements
were taken every 10 min until full lysis of the bacterial culture
occurred. At least three biological and technical replicates were
performed.
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